Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

The prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2DM) is believed to be ~70% and that of advanced fibrosis ~20%. Given the magnitude of the problem, there is a real sense of urgency to identify the best pharmacological approach for to treat both diabetes and NASH in this population. Vitamin E is recommended for patients with biopsy-proven NASH without diabetes but did not have similar efficacy in a recent proof-of-concept RCT in patients with T2DM. Regarding antidiabetic agents, there is a significant amount of data for some agents but much more limited information for others. Among insulin-sensitizers, while metformin has not shown significant benefit, pioglitazone has been incorporated into current treatment guidelines for patients with or without T2DM and biopsy-proven NASH. This article is protected by copyright. All rights reserved.

[1]  K. Cusi,et al.  Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. , 2019, The Journal of endocrinology.

[2]  N. Lundbom,et al.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study , 2018, Diabetes, obesity & metabolism.

[3]  S. Mudaliar,et al.  Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[4]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[5]  N. Sattar,et al.  Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[6]  Hassan Neishaboori,et al.  Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease , 2018, Clinical and molecular hepatology.

[7]  Shahinul Alam,et al.  Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial , 2018, Hepatic medicine : evidence and research.

[8]  S. Nielsen,et al.  Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes , 2018, Diabetes, obesity & metabolism.

[9]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[10]  J. Holst,et al.  Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial , 2018, Diabetes, obesity & metabolism.

[11]  K. Cusi,et al.  Modulation of Insulin Resistance in NAFLD. , 2018, Hepatology.

[12]  Dalong Zhu,et al.  Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease , 2017, Journal of diabetes.

[13]  T. Yoshimoto,et al.  Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. , 2017, Endocrine journal.

[14]  C. McKenzie,et al.  Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. , 2017, World journal of gastroenterology.

[15]  O. Chevallier,et al.  Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study , 2016, The Journal of clinical endocrinology and metabolism.

[16]  Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019 , 2018 .

[17]  K. Cusi,et al.  Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. , 2016, Endocrinology and metabolism clinics of North America.

[18]  A. Chang,et al.  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[19]  P. Pouwels,et al.  Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial , 2016, Diabetologia.

[20]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[21]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[22]  R. Wagner,et al.  A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus , 2016, Drugs in R&D.

[23]  P. Hytiroglou,et al.  Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. , 2016, Diabetes research and clinical practice.

[24]  Laurentiu M. Pop,et al.  Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. , 2016, The Journal of clinical endocrinology and metabolism.

[25]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[26]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[27]  H. Mitsui,et al.  Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury , 2015, SpringerPlus.

[28]  T. Sasaoka,et al.  Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. , 2015, Diabetes research and clinical practice.

[29]  J. D. De Guise,et al.  Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial , 2015, Diabetes Care.

[30]  Hirokazu Takahashi,et al.  Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[31]  D. Brenner,et al.  Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.

[32]  J. Sowers,et al.  Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function , 2015, Diabetes.

[33]  M. Imamura,et al.  Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. , 2014, Hepato-gastroenterology.

[34]  M. Omata,et al.  The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone , 2012, TheScientificWorldJournal.

[35]  A. Morabito,et al.  Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta‐analysis , 2011, Diabetes, obesity & metabolism.

[36]  Y. Terauchi,et al.  Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. , 2011, Hepato-gastroenterology.

[37]  R. Muthupillai,et al.  Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial , 2011, Diabetologia.

[38]  Y. Terauchi,et al.  Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice , 2011, Diabetes.